Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant
Deal Brings Pfizer Another Prostate Cancer Offering
Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications.
You may also be interested in...
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.